Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

1.818 -0.122 (-6.28%)
Streaming Delayed Price Updated: 10:06 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adagene Inc. - ADS, each representing 1.25 ordinary shares

< Previous 1 2 Next >
Adagene announces up to $25 million strategic investment from Sanofi
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Jefferies Global Healthcare Conference 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Leerink’s Global Healthcare Conference 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
From Adagene Inc.
Via GlobeNewswire
Adagene to Participate in Investor Conferences in September
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Investor Conferences in June
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
From Adagene Inc.
Via GlobeNewswire
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Investor and Scientific Conferences in September
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.